---
title: "Amgen Says Tezspire Safety Profile Consistent With Approved Indications"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297133742.md"
datetime: "2026-08-27T06:31:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297133742.md)
  - [en](https://longbridge.com/en/news/297133742.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297133742.md)
generator: "portal-rs"
---

# Amgen Says Tezspire Safety Profile Consistent With Approved Indications

Aug 27 (Reuters) - Amgen Inc (AMGN.O) : \* TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS \* AMGEN - TEZSPIRE SAFETY PROFILE CONSISTENT WITH APPROVED INDICATIONS Source text: Further company coverage: (AMGN.O)

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [UK regulator suspends Amgen's Tavneos for new patients over unreliable data](https://longbridge.com/en/news/297642592.md)
- [8,321 Shares in Amgen Inc. $AMGN Bought by Glenview Trust Co](https://longbridge.com/en/news/297400065.md)
- [Strait & Sound Wealth Management LLC Invests $1.92 Million in Amgen Inc. $AMGN](https://longbridge.com/en/news/297400046.md)
- [Rare-Disease Drug Tavneos Faces UK Withdrawal](https://longbridge.com/en/news/297819339.md)
- [MASTERINVEST Kapitalanlage GmbH Makes New Investment in Amgen Inc. $AMGN](https://longbridge.com/en/news/297303269.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**